[New antiplatelet agents].
Aspirin has set the gold standard for platelet inhibition in prophylaxis and treatment of cardiovascular diseases. Invasive techniques and novel platelet-inhibitors have fundamentally changed therapeutic approaches to antithrombotic treatment and further diversification is to be expected in the future. Three trends are essentially obvious: 1) the combination of established inhibitors such as aspirin with ticlopidine or clopidogrel, 2) the use of new IIb/IIa antagonists in various molecular forms, pharmacologies and doses and 3) the combination of established platelet-inhibitors with theses novel IIIb/IIIa antagonists.
Beer
J H
JH
Departement Innere Medizin, Kantonsspital Baden.
D006801:Humans; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D013923:Thromboembolism / Q000097:blood / Q000188:drug therapy*
D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex
Neue Plättchenhemmer.